A study of fomotidine preventing weight gain olanzapine-induced / 中国基层医药

ABSTRACT

Objeetive To study the therapeutic effect of the H2 antagonist fomotidine on preventing weight gain olanzapine-induced.Methods Forty first-episode CCMD-3 schizophrenia patients were randomly allocated to received either famotidine or placebo in addition to olanzapine for 8 weeks.Their body weights and heights were measured before treatment and 2 weeks,4 weeks,8 weeks after treatment to calculate the body mass index and the percentage of patients gained more than 7% of initial bpdy weight after 8 weeks.SAPS and SANS were selected to evaluate the therapeutic effect.Results While the weight and the body mass index of patients in two groups after 2 weeks,4 weeks,8 weeks post-treatment increased significantly compared with those of pre-treatment(P＜0.05).The weight of patients in two groups gained 3.7kg at the edd of 8 weeks,and the BMI increased 2.5 or 2.6 kg/cm2,reapectively.However 8 weeks later,the difference between two groups wan not significant(P＞0.05).The difference between two groups on the percentage of patients gained more than 7% of initial body weight at the end of 8 weeks Wan not significant(P＞0.05).The sCOres of SAPS and SANS at the end of 8 weeks decreased significantly compared with those of the baseline(P＜0.05),but the difference between two groups was not significant(P＞0.05).Conclusion Allocated to the H2 antagonist fomotidine could not reduce weight gain olanzapine-induced.